WKN DE: A14UQC / ISIN: FR0012333284

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV		Knock-Outs
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime
Kurs + Chart
Chart (groß)
Times + Sales
Chartvergleich
Börsenplätze
Realtime Push
Orderbuch
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Aktion
Portfolio
Watchlist

Abivax Times and Sales (STU)

Zeit	Kurs	Umsatz (Stk)
21:56:10	102,600
21:47:05	103,200
21:32:36	103,200
21:17:58	103,400
21:04:14	103,800
20:48:24	103,800
20:32:52	103,400
20:18:18	103,800
20:03:32	104,200
19:50:42	104,600	50
19:48:24	104,600
19:33:04	104,600
19:18:31	104,600
19:04:17	103,800
18:48:24	104,000
18:35:17	104,000
18:35:06	104,000
18:02:41	106,000
17:47:15	106,600
17:31:44	106,200
17:17:27	106,200
17:02:40	106,600
16:47:12	106,000
16:32:12	105,800
16:17:18	106,400
15:47:31	105,000
15:32:03	103,800
15:17:14	104,400
15:02:09	104,200
14:47:09	104,000
14:36:19	104,400	40
14:31:55	104,000
14:17:09	103,800
14:02:37	103,400
13:47:12	103,400

Kursrückgang	Kursanstieg	keine Kursänderung
(Balkenlänge beschreibt das Umsatzvolumen)

Nachrichten zu Abivax SA

07.01.26		EQS-News: Abivax Provides 2026 Corporate Outlook
18.12.25		EQS-News: Abivax to be Added to Nasdaq Biotechnology Index
17.12.25		EQS-News: Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
15.12.25		EQS-News: Abivax Presents Third Quarter 2025 Financial Results
05.10.25		EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
29.09.25		EQS-News: Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
23.09.25		EQS-News: Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
12.09.25		EQS-News: Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

Analysen zu Abivax SA

Weitere Meldungen

23:05		3 AI Infrastructure Stocks to Buy as the Market Heads Toward $1.4 Trillion by 2030
23:03		Gewinnmitnahmen nach Rally: Intel-Schock drückt die Stimmung an der Wall Street
22:46		Why Broadcom Stock Fell Today
22:45		Soon, You Can Cut Through Stadium Cellular Congestion With Turbo Live by AT&T
22:40		Where Will Broadcom Stock Be by December 2026?
22:39		Deal Dispatch: Billionaire Circles Cricket's RCB, Nestlé Water Sale Heats Up
22:30		$1000 Invested In Thermo Fisher Scientific 20 Years Ago Would Be Worth This Much Today
22:22		JPMorganChase Company Update 2026
22:20		Tesla Saw Cybertruck Sales Plunge 48% In 2025: Will Deliveries In Middle East Help Offset Dried-Up Demand?
22:19		Brand Engagement Network (BNAI) Stock Explodes On $2 Million Valio Technologies Deal
22:15		Here's How Much $100 Invested In Royal Caribbean Gr 5 Years Ago Would Be Worth Today
22:15		1 Stock I'd Buy Before FTAI Aviation in 2026
22:05		These Disaster Readiness Essentials Can Save You a Lot of Trouble and Make Big Snow Days Less Daunting
22:05		Cathie Wood Thinks AMD Will Challenge Nvidia This Year
22:03		Lululemon Founder Outraged Over See-Through Leggings: 'A New Low'
22:02		Today's Wordle Hints, Answer and Help for Jan. 24, #1680
22:01		Beyond The Numbers: 25 Analysts Discuss Oracle Stock
22:01		What Analysts Are Saying About Under Armour Stock
22:00		Expert Outlook: Chord Energy Through The Eyes Of 8 Analysts
22:00		Here's How Much $100 Invested In Vanguard Information Tech ETF 20 Years Ago Would Be Worth Today
22:00		P/E Ratio Insights for KKR
21:55		Accelerant ARX Q3 2025 Earnings Call Transcript
21:51		SanDisk (SNDK) Stock Extends Pullback As AI Memory Rally Catches Its Breath
21:50		Fable Reboot Set for Fall 2026 as RPG Franchise Debuts on PS5
21:49		Options Corner: Lingering Fears Have Sharply Discounted Nvidia Stock Call Spreads
21:45		If You Invested $100 In Trilogy Metals Stock 10 Years Ago, You Would Have This Much Today
21:44		Goldman paid CEO David Solomon $47mn in 2025 as its stock soared
21:41		What's Going On With Shares of OLB Group?
21:30		If You Invested $1000 In MP Materials Stock 5 Years Ago, You Would Have This Much Today
21:29		Inflation is an ‘economic thief.’ Can the Fed finally arrest the frustrating rise in prices?
21:23		Saudi Arabia-Backed LIV Golf to Hold Tournament at the Trumps’ New Jersey Resort
21:23		Top Stocks to Double Up on Right Now
21:15		TikTok Updates Its Terms and Conditions in the U.S.
21:15		$1000 Invested In Danaher 10 Years Ago Would Be Worth This Much Today
21:14		Hancock Prospecting, Maaden enter JV to ramp up exploration in Saudi Arabia
21:14		What's Fueling The Surge in Microsoft Stock?
21:06		What's Going On With Super League Stock?
21:05		Here Are My Top 3 High-Yield Stocks to Buy Now
21:01		What Analysts Are Saying About Banc of California Stock
21:01		A Glimpse Into The Expert Outlook On Jacobs Solutions Through 9 Analysts
21:00		What Analysts Are Saying About Neurocrine Biosciences Stock
21:00		12 Analysts Have This To Say About Citizens Financial Group
21:00		Applied Digital's Options Frenzy: What You Need to Know
21:00		Deep Dive Into ConocoPhillips Stock: Analyst Perspectives (11 Ratings)
21:00		Is Roma Green Finance Ltd Gaining or Losing Market Support?
21:00		How Do Investors Really Feel About Coupang Inc?
21:00		$100 Invested In Coherent 10 Years Ago Would Be Worth This Much Today
21:00		A Look Into Spotify Technology Inc's Price Over Earnings
21:00		Forecasting The Future: 6 Analyst Projections For Weatherford International
21:00		What's Driving the Market Sentiment Around Corvus Pharmaceuticals Inc?

1 | Weiter

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Weitere Aktien: Graham Holdings BCP Finance Newera Resources Flying Monkey Capital The Babcock & Wilcox

Kontakt - Impressum - Werbung - Barrierefreiheit

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2026 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 79% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	23.01.2026 23:44
Kaufwert:	EUR
	Hinzufügen Speichern

Abivax Aktie

WKN DE: A14UQC / ISIN: FR0012333284

Abivax Times and Sales (STU)

Nachrichten zu Abivax SA

Analysen zu Abivax SA

Weitere Meldungen